[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.146.179.146. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
October 24/31, 2001

Linezolid and Reversible Myelosuppression—Reply

Author Affiliations
 

Stephen J.LurieMD, PhD, Senior EditorIndividualAuthorJody W.ZylkeMD, Contributing EditorIndividualAuthor

JAMA. 2001;286(16):1973-1974. doi:10.1001/jama.286.16.1969

In Reply: Since our letter was published, we have observed 10 additional patients with anemia, reticulocytopenia, and increasing iron saturation. These patients ranged in age from 24 to 81 years (7 women, 3 men), and all received linezolid (600 mg twice per day) for at least 2 weeks. Some of these patients were taking several medications and others received only linezolid. In all cases, the iron saturation and reticulocyte count returned to normal when linezolid was discontinued. Dr Abena and colleagues observed this same effect in their patient with sideroblastic anemia while receiving linezolid.

First Page Preview View Large
First page PDF preview
First page PDF preview
×